SUBSCRIBE
SUBSCRIBE
News   Drug Development

Bioheart, Inc. Provides Update: Clinical Studies Strategy and Progress

January 11, 2011 | 
1 min read
SUNRISE, Fla., Jan. 10, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) announced today that Bioheart's primary focus is on completing clinical evaluation of its cell therapies for treating heart failure and related cardiac diseases.
Clinical research Phase 2 Phase 3
MORE ON THIS TOPIC
Red round circle with a pause button or icon against yellow background.
Gene therapy
Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study
February 9, 2026
 · 
1 min read
 · 
Tristan Manalac
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Gene therapy
Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies
February 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Graphic drawing white background
Psychedelics
AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing
February 6, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Immunology and inflammation
Priovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study
February 6, 2026
 · 
2 min read
 · 
Tristan Manalac